Condition 1: End stage renal disease on hemodialysis. Condition 2: Anemia. Dependence on renal dialysis End stage renal disease
Conditions
Interventions
Intervention 1: Intervention group: 30 hemodialysis patients enroll in the study using 30 mg zinc gluconate tablets containing 30 mg elemental zinc (Dineh pharmaceutical Co., Tehran, Iran). The patien
and on dialysis days, after the meal post dialysis session
daily for 6 months. The drug will be offered in hemodialysis ward weekly and to make sure the drug is taken by the patients, they are asked to return the empty box. Intervention 2: Control group: 30 h
for 6 months. The patients will receive the placebo in hemodialysis wards weekly and to make sure the drug is taken by the patients, they are asked to return the empty box.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients who have been on hemodialysis for at least 3 months More than 18 years of age Consensus on participation in the study Hemoglobin level less than 12 g/dl Patients who are under ongoing therapy with injected erythropoetin Not taking cholrthalidone, tetracycline and penicillin Non pregnant and breastfeeding On hemodialysis for at least twice a week Not having cancer, acute inflammatory disease and severe hepatic failure
Exclusion criteria
Exclusion criteria: Patients wanting to discontinue the cooperation for any reason Discontinuing hemodialysis therapy Surgical operation during the study Blood transfusion during the study Hemorrhage during the study Development of malignant tumors during the study Pregnancy during the study Intolerance of drug Non-compliance with the intervention (less than 70%)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood hemoglobin level. Timepoint: Before, 3 and 6 months after the intervention. Method of measurement: Hemoglobin measurement by automated hematology analyzer, sysmex-21N, Japan. | — |
Secondary
| Measure | Time frame |
|---|---|
| The amount of prescribed erythropoetin. Timepoint: Before, 3 and 6 months after the intervention. Method of measurement: By observation and questionnaire.;Serum zinc level. Timepoint: Before, 3 and 6 months after the intervention. Method of measurement: Laboratory AUDIT kit (Delta Darman Part, Tehran, Iran), measured by OLYMPUS 2700 autoanalyzer, Japan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShiva Seirafian
Esfahan University of Medical Sciences
Outcome results
None listed